$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Trigeminal neuralgia is a disorder associated with intense episodes of lancinating pain in the distribution of the trigeminal nerve. The severity of this pain can result in significant patient anxiety, malnutrition and even depression3. While possible proximal etiologies of this condition are diverse and include neoplasm or demyelination, 80-90% of cases are related to compression of the trigeminal nerve by an adjacent vessel4,5. In many cases of trigeminal neuralgia, pharmacological treatment is sufficient for adequate control of symptoms. However, the majority of patients require more definitive surgical measures6. Both microvascular decompression (MVD) and ablative procedures (e.g., radiosurgery, percutaneous radiofrequency lesioning, balloon compression, or glycerol rhizolysis) have been shown to be effective at controlling trigeminal neuralgia symptoms acutely—however, MVD has been demonstrated to be superior in preventing long-term recurrence7.
Since the first reported uses of MVD by Janetta in the 1960s, adaptations to the procedure have improved patient outcomes. The use of intraoperative auditory brainstem evoked potentials, in particular, has lessened surgical morbidity by monitoring for early irritation of the brainstem and cranial nerves and assisting in prevention of damage to these structures8. Recent reports estimate positive outcome rates of MVD for trigeminal neuralgia in the ranges of 77-94%9,10,11. Nevertheless, significant postoperative complications, namely CSF leak, cerebellar damage and hearing loss9,10, still occur with the procedure. Additionally, recurrence of symptoms has been reported to occur in as many as 39% of patients10,11 following this procedure. In addition to being correlated with intraoperative variables such as nerve location, blood vessel, type and duration of symptoms6,7, the rate of recurrence also has been correlated with experience of the surgeon and hospital in performing MVD12. With proper technique, patient outcome can be maximized and adverse outcomes can be reduced.
This study examined the effectiveness of the surgical technique of MVD performed by two neurosurgeons at Vanderbilt University. The positive outcome rate we measured (93%) is at the high range of those generally reported in the literature9,10. While average duration of follow-up in this series is small, patients are routinely not seen in clinic following the 6-week visit if they remain pain-free and asymptomatic. Given that 64% of patients reported themselves to be entirely pain-free following the procedure, it is not surprising that the average duration of follow-up in this study is short. Present complication rates at our institution are comparable to those reported by others. Initially, MVDs were performed with a suboccipital craniectomy without replacement of the bone flap. After an internal review of the data, which demonstrated an elevated CSF leak of 25%, the protocol was changed to include buttressing with either a methylmethacrylate flap or replacement of the bone flap prior to wound closure. Since this time, our CSF leak rate has approximated 8%—consistent with other rates (2.4 – 12%) reported in the literature7,13. The percentage of our patients reporting hearing loss (3%) also approximates figures reported in the literature (0.8-2.8%)1,2,12,13, . In no instance did we have a patient with evidence cerebellar damage.
Our experience suggests that monitoring with BAERs and bone flap replacement are worthwhile options in microvascular decompression. The salient surgical principles and technical nuances utilized at Vanderbilt University have been presented in video format. Furthermore, this video journal format uniquely presents the vascular pathology that many physicians do not routinely see outside the operating room. The results presented suggest that microvascular decompression can be a highly effective procedure performed with low patient morbidity.